Medical Marijuana 411 (MM411), a leading global provider of digital cannabis education, has launched a collaboration
with CReDO Science, led by Dr. Ethan Russo, a board-certified neurologist and medical cannabis clinician and researcher, to deliver accurate, evidence-based cannabis and endocannabinoid system education. An
initial foundational class developed by Dr. Russo, MM411 President Christine DeVol, and Nishi Whiteley, MS, Chief Operating Officer of CReDO Science, is now available in English, Spanish, and Japanese through MM411 and features 8 webinar modules totaling
11 hours, with an expanded, follow-up class planned for September.
“We are thrilled to join forces with CReDO Science to offer this unparalleled digital cannabis education platform,” said DeVol. “By combining our expertise in digital education
with Dr. Russo’s extensive research and clinical expertise, we are poised to greatly improve the quality of cannabis education available to all as we create a legacy of his decades of groundbreaking work.”
“Cannabis has immense therapeutic potential, but misinformation and stigma often cloud its true benefits and medical use,” said Dr. Russo. “Through this collaboration with MM411 we hope to
empower healthcare professionals, patients, and advocates around the globe with accurate, science-backed knowledge to fully understand the risks and benefits of cannabis use. Together, we can transform the cannabis landscape.”
Through the collaboration, Dr. Russo is distilling decades of peer-reviewed scientific studies along with his 28 years of clinical cannabis experience to ensure students receive the most
accurate and up-to-date information on cannabis and its potential medical applications in a format that is comprehensible to a wide-reaching audience of medical professionals, patients, caregivers, advocates, and industry workers.
As part of the experience, Dr. Russo incorporates detailed citations throughout course materials, allowing students to understand from where his lessons are based and granting them further
access to the tools they will need to dive deeper.
The initial course offering aims to demystify the mechanisms by which cannabis components interact with the human body. It will make understandable the science behind cannabis and the human
endocannabinoid system. This will empower healthcare professionals to integrate cannabis in their practices, patients looking to understand the science behind their treatment, and industry professionals to better serve their customers. By helping learners
to make informed decisions about its use, the program will contribute to the safety and efficacy of cannabis consumption worldwide.
Cannabis use is growing worldwide evidenced by The United Nations World Drug Report of 2023 which estimates 219 million people worldwide use cannabis. The US government report 2022 National
Survey on Drug Use and Health estimates 59 million people 18 and older used cannabis in the year prior. But cannabis education has fallen behind. According to the journal article, Physicians-in-training are not prepared to prescribe medical marijuana by Evanoff
et al, 89.5% of residents and fellows graduating from American medical schools felt they were not at all prepared to prescribe medical marijuana, 35.3% felt not at all prepared to answer questions, and 84.9% reported receiving no education in medical school
or residency on medical marijuana. The report further outlined only 9% of medical school curriculums included content on medical cannabis.
About MM411
Founded in 2009, MM411 is a global leader in medical cannabis education. Thousands of medical professionals from 20 different countries have taken MM411 research-based cannabis courses. With cannabis education programs
approved by more U.S. states than any other organization, MM411 offers medical cannabis certifications and aligns with government entities to develop certification programs for medical and industry professionals, U.S. state-required certifications for healthcare
professionals, and cannabis consultants (budtenders). Certifications are focused on areas such as federal and state marijuana laws, science, endocannabinoid system, approved conditions, safe handling, dispensary customer service, how to use various product
methods, and dosing.
About CReDO Science
CReDO Science
is a private company that offers licensing of its innovations, provides clinical cannabis research consulting and formulation and product development consulting for wellness,
medical, adult-use and pharmaceutical products.
